AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn.
Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia.
Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments.
The company, through its subsidiary, BioNexus Gene Lab Sdn.
Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers.
The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Country | MY |
IPO Date | Jan 8, 2021 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 30 |
CEO | Su-Leng Tan |
Contact Details
Address: Tower B, Vertical Business Suite Kuala Lumpur, MY | |
Website | https://www.bionexusgenelab.com |
Stock Details
Ticker Symbol | BGLC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001737523 |
CUSIP Number | 090628108 |
ISIN Number | US0906282076 |
Employer ID | 26-2124961 |
SIC Code | 8071 |
Key Executives
Name | Position |
---|---|
Su-Leng Tan | Chief Executive Officer, Acting Chief Financial Officer, Secretary & Director |
Kwan Wah Chan | Marketing Manager |
Too Kam Tham | Managing Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 02, 2025 | 8-K | Current Report |
Nov 15, 2024 | 10-Q | Quarterly Report |
Nov 14, 2024 | NT 10-Q | Filing |
Nov 08, 2024 | 8-K | Current Report |
Oct 15, 2024 | 8-K | Current Report |
Oct 10, 2024 | 8-K | Current Report |
Sep 25, 2024 | 8-K | Current Report |
Sep 18, 2024 | 8-K | Current Report |
Sep 16, 2024 | DEF 14A | Filing |
Sep 12, 2024 | 8-K | Current Report |